Chinese immunotherapy biotech I-Mab Biopharma (IMAB) plans to raise $100 million at an $876 million market cap. I-Mab would be the first Chinese biotech to IPO in the US in over two years and the second largest Chinese biotech to IPO in the US ever.
Chinese cancer diagnostics provider AnPac Bio-Medical Science (ANPC) plans to raise $22 million at a $150 million market cap.
Lock-up periods will be expiring for nine companies. On Tuesday, January 14: Fulcrum Therapeutics (FULC), Mirum Pharmaceuticals (MIRM), and Phreesia (PHR). On Wednesday, January 15: Innate Pharma (IPHA).
Street research is expected for Monopar Therapeutics (MNPR) on Monday, January 13.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.